Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
Q96RJ3
UPID:
TR13C_HUMAN
Alternative names:
B-cell-activating factor receptor; BAFF receptor; BLyS receptor 3
Alternative UPACC:
Q96RJ3
Background:
Tumor necrosis factor receptor superfamily member 13C, also known as the B-cell-activating factor receptor (BAFF receptor), plays a pivotal role in B-cell survival and response. It specifically binds to TNFSF13B/BAFF, promoting mature B-cell survival and enhancing the B-cell response. This receptor is crucial for B-cell differentiation and immunoglobulin secretion.
Therapeutic significance:
The protein is directly linked to Immunodeficiency, common variable, 4, a disease characterized by antibody deficiency and recurrent bacterial infections due to impaired B-cell differentiation. Understanding the role of Tumor necrosis factor receptor superfamily member 13C could open doors to potential therapeutic strategies for treating immunodeficiency disorders.